shilly
Active Member
What other choice to we have to vote for? The NDP aren't going to help, might make more problems than we already have...
Last edited by a moderator:
Toronto MaRS Centre Phase 2 | 112.77m | 20s | Alexandria | B+H
What other choice to we have to vote for? The NDP aren't going to help, might make more problems than we already have...
urbandreamer
recession proof
Cranes are coming down today--1 hour ago I spotted a crane and trailer and crew starting to take apart one of the tower cranes.... Guess this project is finished?
Proof:
Proof:
Last edited:
OldManKensey
Active Member
How very sad. At least the Bay Adeliade stump was somewhat hidden on Temperance Street. This abandoned site will be an eyesore on a prestigous intersectoin for some time. Could the random bits of elevator shaft and support column that I think are above grade be passed of as modern art of some sort?
SP!RE
°°°°°°
Anything can be art--- technically it is a monument to the economic times we're in. Nothing much to be worried about--- at least it's interesting.
I just hope they don't alter the design when it does indeed get built. They had created a hopelessly gorgeous design-- very sleek and very engaging. I loved every detail of it!
I just hope they don't alter the design when it does indeed get built. They had created a hopelessly gorgeous design-- very sleek and very engaging. I loved every detail of it!
DAMB
New Member
another projects I'm working on on hold.
taal
Senior Member
Anymore inside info about this one DAMB?
We had a few rumors floating around a while ago that it was going to be canceled all together and possibly moved to another site outside Toronto?
It doesn't really help to perpetuate rumours like that Taal. Firstly, outright cancellation is simply pure, uninformed, speculation. Secondly, you were the one that introduced the SSC Mississauga rumor to UT, and it was pretty much shot down. Until there are new official announcements, we do not need new misinformation.
42
42
Automation Gallery
Superstar
Maybe The Toronto General can build an extra wing to its already busy hospital.
Here is a design that would probably fit nice in that location,
http://images.google.ca/imgres?imgu...nt+hospital+villager&gbv=2&ndsp=20&hl=en&sa=N
http://images.google.ca/imgres?imgu...al+villager&start=20&gbv=2&ndsp=20&hl=en&sa=N
Here is a design that would probably fit nice in that location,
http://images.google.ca/imgres?imgu...nt+hospital+villager&gbv=2&ndsp=20&hl=en&sa=N
http://images.google.ca/imgres?imgu...al+villager&start=20&gbv=2&ndsp=20&hl=en&sa=N
Last edited:
DAMB
New Member
I was told that they still plan on going ahead may a soon as sept. but that is all talk nothing confirmed.
The major issue with this project was that the mech. engineer really messed up this project. They designed the systems too small which are on the second floors and had to redesign them, thus adding millions to the cost of the project. At the same time a major leaser pulled out, so with today’s economy it did make sense to spend the money on a building that was going to sit half empty.
All this may have been mentioned before.
SP!RE
°°°°°°
No-- that's brand new information. And fascinating. Well we will keep our fingers crossed.
Given the purpose of this building and its program, I feel that it could be built before the economy normalizes. That wouldn't shock me.
However, I am prepared to wait five years or so.
Given the purpose of this building and its program, I feel that it could be built before the economy normalizes. That wouldn't shock me.
However, I am prepared to wait five years or so.
androiduk
Senior Member
The company building this (Alexandria Real Estate Equities) has had some success recently signing big tenants to it's U.S. holdings. Keep your fingers crossed.
---------------------------------------------------------------------------------------------------------------------
Large Cap Biopharma Company Signs New Lease at Mission Bay Life Science Cluster
Technology Square Attracts Pfizer Inc.
Additional LEED (R) Certifications Awarded
PASADENA, Calif., Dec. 23/PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), Landlord of Choice to the Life Science Industry(R), today provided an update highlighting its unique and proprietary business model, including its announcement of the extension to 2010 of a key $175 million debt maturity from 2009. Additionally, the Company is on track to post another solid leasing quarter including new leases signed in San Francisco, California and Cambridge, Massachusetts with leading pharmaceutical and biopharmaceutical companies.
A multinational, large cap biopharmaceutical company has entered into a long-term lease at the multi-tenant building at 1500 Owens Street, The Alexandria Center for Science and Technology at Mission Bay in San Francisco, California. The Alexandria Center for Science and Technology at Mission Bay is home to leading life science entities, including Pfizer Inc., Merck & Co., Inc., University of CaliforniaSan Francisco and the J. David Gladstone Institutes; which is complemented by leading and well-capitalized private companies such as Presidio Pharmaceuticals, Inc., Five Prime Therapeutics, Inc. and Ion Torrent Systems, Inc., with blue chip venture capital backing.
Alexandria also reported that Pfizer Inc. has entered into a long-term lease at Technology Square in Cambridge, Massachusetts. Pfizer will be locating its Capsugel division, a global leader in dosage form development and capsugel manufacturing, to the renown Technology Square cluster. This announcement marks the second Alexandria life science cluster in which Pfizer will be resident. Pfizer signed a long-term lease in August 2008 to house its Biotherapeutics and Bioinnovation Center at The Alexandria Center for Science and Technology at Mission Bay.
Capsugel is at the forefront of drug delivery innovation. Its diverse product line includes hard gelatin, softgel, non-animal and fish gelatin capsules. As the leading global gelatin capsule manufacturer, Capsugel is the most experienced company in its field.
Joel S. Marcus, Chairman and Chief Executive Officer of Alexandria Real Estate Equities, Inc., stated, "We are delighted to welcome Pfizer to our vibrant and entrepreneurial life science cluster at Technology Square in Cambridge. We believe that Pfizer's decision to locate its Capsugel division to Technology Square is a direct reflection of the strength of our life science cluster locations, proprietary products and unique class-A office/laboratory facilities. Pfizer will be joining leading life science entities, including Novartis Institutes for BioMedical Research and Sirtris Pharmaceuticals, Inc., a GlaxoSmithKline plc company. With a strategic presence at Technology Square, Pfizer will increase access to the cluster's flow of high-quality, innovative new therapeutic candidates and programs, cutting-edge technologies and deep talent pool in efforts to harvest future pipeline products."
In commenting on the importance of being located at Technology Square, Dr. Michelle Dipp, Vice President, Corporate Development at Sirtris, stated, "Sirtris and the Center of Excellence for External Drug Discovery are in the hub of top science at Technology Square in Cambridge. It is key for us to readily have the opportunity to access the top academic research and scientific innovation in the area." Upon acquiring Sirtris, GlaxoSmithKline plc made the strategic decision to keep Sirtris as a stand-alone, entrepreneurial unit at Technology Square.
Alexandria has a very broad and diversified quality client tenant base. As of September 30, 2008, on a rental revenue basis by sector, Alexandria's multinational pharmaceutical client tenants represented approximately 25% of the client tenant mix, led by Novartis AG and GlaxoSmithKline plc; public biopharmaceutical companies represented approximately 26% and included the six largest in the sector, Genentech, Inc., Amgen Inc., Gilead Sciences, Inc., Celgene Corporation, Genzyme Corporation, and Biogen Idec, Inc.; private biopharmaceutical represented approximately 13% and were dominated by high-quality, leading-edge companies with blue chip venture investors, including Ambrx, Inc., Anaphore, Inc., BIND Biosciences, Inc., Fate Therapeutics, Inc., Juvaris BioTherapeutics, Inc. and TolerRx, Inc.; revenue producing life science products and service companies represented approximately 14%, led by Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings and Monsanto Company; government agencies and renown medical and research institutions represented approximately 14%, including The Scripps Research Institute, the Massachusetts Institute of Technology, the Fred Hutchinson Cancer Research Center, the University of Washington and the U.S. Government; and the remainder of approximately 8% was comprised of traditional office. The two fastest growing sectors by revenue currently include leading institutional and multinational pharmaceutical client tenants. Alexandria's innovative business model, very strong and unique life sciences and financial underwriting skills with substantial experience and expertise, long-term client tenant relationships and sophisticated management with both real estate and life science operating experience and expertise, set Alexandria apart from all other publicly-traded REITs. From Alexandria's IPO (May 1997) through September 30, 2008, Alexandria was the number two publicly-traded equity REIT with a total return of 819%.
Two of Alexandria's properties were recently granted LEED(R) certification. 200 Technology Square in Cambridge, Massachusetts has been LEED(R) certified Gold by the U.S. Green Building Council (USGBC) for its Core and Shell conversion. In addition, 249 East Grand Avenue in South San Francisco, California received LEED(R) Silver certification for Core and Shell new construction.
"200 Technology Square's LEED(R) certification demonstrates tremendous green building leadership," said Rick Fedrizzi, President, Chief Executive Officer and Founding Chair of the U.S. Green Building Council. "The urgency of USGBC's mission has challenged the industry to move faster and reach further than ever before and Alexandria Real Estate Equities serves as a prime example with just how much we can accomplish."
LEED(R) is the nationally accepted benchmark for the design, construction and operation of high performance green buildings. LEED(R) promotes a whole-building approach to sustainability by recognizing performance in five key areas of human and environmental health: sustainable site development, water savings, energy efficiency, materials selection and indoor environmental quality. Core and Shell encompasses base building elements such as structure, envelope and the HVAC system.
Alexandria continues to innovate and lead the way in green initiatives for its sector, as evidenced by these latest achievements. Silver LEED(R) certification for Core and Shell was also granted for the Company's build-to-suit property located at 681 Gateway, South San Francisco, California as previously announced. This was the first Core and Shell project to be LEED(R) Silver certified in the State of California. Alexandria's state-of-the-art, sustainable building design assures functional and energy efficiency, systems integration, reliability and cost effectiveness.
Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry(R), is the largest owner and pre-eminent first-in-class real estate investment trust focused principally on science-driven cluster formation. Alexandria is the leading provider of high-quality environmentally sustainable real estate, technical infrastructure and services to the broad and diverse life science industry. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biopharmaceutical, medical device, product, service, and translational entities, as well as government agencies. Alexandria's operating platform is based on the principle of "clustering", with assets and operations located in key life science markets.
---------------------------------------------------------------------------------------------------------------------
Large Cap Biopharma Company Signs New Lease at Mission Bay Life Science Cluster
Technology Square Attracts Pfizer Inc.
Additional LEED (R) Certifications Awarded
PASADENA, Calif., Dec. 23/PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), Landlord of Choice to the Life Science Industry(R), today provided an update highlighting its unique and proprietary business model, including its announcement of the extension to 2010 of a key $175 million debt maturity from 2009. Additionally, the Company is on track to post another solid leasing quarter including new leases signed in San Francisco, California and Cambridge, Massachusetts with leading pharmaceutical and biopharmaceutical companies.
A multinational, large cap biopharmaceutical company has entered into a long-term lease at the multi-tenant building at 1500 Owens Street, The Alexandria Center for Science and Technology at Mission Bay in San Francisco, California. The Alexandria Center for Science and Technology at Mission Bay is home to leading life science entities, including Pfizer Inc., Merck & Co., Inc., University of CaliforniaSan Francisco and the J. David Gladstone Institutes; which is complemented by leading and well-capitalized private companies such as Presidio Pharmaceuticals, Inc., Five Prime Therapeutics, Inc. and Ion Torrent Systems, Inc., with blue chip venture capital backing.
Alexandria also reported that Pfizer Inc. has entered into a long-term lease at Technology Square in Cambridge, Massachusetts. Pfizer will be locating its Capsugel division, a global leader in dosage form development and capsugel manufacturing, to the renown Technology Square cluster. This announcement marks the second Alexandria life science cluster in which Pfizer will be resident. Pfizer signed a long-term lease in August 2008 to house its Biotherapeutics and Bioinnovation Center at The Alexandria Center for Science and Technology at Mission Bay.
Capsugel is at the forefront of drug delivery innovation. Its diverse product line includes hard gelatin, softgel, non-animal and fish gelatin capsules. As the leading global gelatin capsule manufacturer, Capsugel is the most experienced company in its field.
Joel S. Marcus, Chairman and Chief Executive Officer of Alexandria Real Estate Equities, Inc., stated, "We are delighted to welcome Pfizer to our vibrant and entrepreneurial life science cluster at Technology Square in Cambridge. We believe that Pfizer's decision to locate its Capsugel division to Technology Square is a direct reflection of the strength of our life science cluster locations, proprietary products and unique class-A office/laboratory facilities. Pfizer will be joining leading life science entities, including Novartis Institutes for BioMedical Research and Sirtris Pharmaceuticals, Inc., a GlaxoSmithKline plc company. With a strategic presence at Technology Square, Pfizer will increase access to the cluster's flow of high-quality, innovative new therapeutic candidates and programs, cutting-edge technologies and deep talent pool in efforts to harvest future pipeline products."
In commenting on the importance of being located at Technology Square, Dr. Michelle Dipp, Vice President, Corporate Development at Sirtris, stated, "Sirtris and the Center of Excellence for External Drug Discovery are in the hub of top science at Technology Square in Cambridge. It is key for us to readily have the opportunity to access the top academic research and scientific innovation in the area." Upon acquiring Sirtris, GlaxoSmithKline plc made the strategic decision to keep Sirtris as a stand-alone, entrepreneurial unit at Technology Square.
Alexandria has a very broad and diversified quality client tenant base. As of September 30, 2008, on a rental revenue basis by sector, Alexandria's multinational pharmaceutical client tenants represented approximately 25% of the client tenant mix, led by Novartis AG and GlaxoSmithKline plc; public biopharmaceutical companies represented approximately 26% and included the six largest in the sector, Genentech, Inc., Amgen Inc., Gilead Sciences, Inc., Celgene Corporation, Genzyme Corporation, and Biogen Idec, Inc.; private biopharmaceutical represented approximately 13% and were dominated by high-quality, leading-edge companies with blue chip venture investors, including Ambrx, Inc., Anaphore, Inc., BIND Biosciences, Inc., Fate Therapeutics, Inc., Juvaris BioTherapeutics, Inc. and TolerRx, Inc.; revenue producing life science products and service companies represented approximately 14%, led by Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings and Monsanto Company; government agencies and renown medical and research institutions represented approximately 14%, including The Scripps Research Institute, the Massachusetts Institute of Technology, the Fred Hutchinson Cancer Research Center, the University of Washington and the U.S. Government; and the remainder of approximately 8% was comprised of traditional office. The two fastest growing sectors by revenue currently include leading institutional and multinational pharmaceutical client tenants. Alexandria's innovative business model, very strong and unique life sciences and financial underwriting skills with substantial experience and expertise, long-term client tenant relationships and sophisticated management with both real estate and life science operating experience and expertise, set Alexandria apart from all other publicly-traded REITs. From Alexandria's IPO (May 1997) through September 30, 2008, Alexandria was the number two publicly-traded equity REIT with a total return of 819%.
Two of Alexandria's properties were recently granted LEED(R) certification. 200 Technology Square in Cambridge, Massachusetts has been LEED(R) certified Gold by the U.S. Green Building Council (USGBC) for its Core and Shell conversion. In addition, 249 East Grand Avenue in South San Francisco, California received LEED(R) Silver certification for Core and Shell new construction.
"200 Technology Square's LEED(R) certification demonstrates tremendous green building leadership," said Rick Fedrizzi, President, Chief Executive Officer and Founding Chair of the U.S. Green Building Council. "The urgency of USGBC's mission has challenged the industry to move faster and reach further than ever before and Alexandria Real Estate Equities serves as a prime example with just how much we can accomplish."
LEED(R) is the nationally accepted benchmark for the design, construction and operation of high performance green buildings. LEED(R) promotes a whole-building approach to sustainability by recognizing performance in five key areas of human and environmental health: sustainable site development, water savings, energy efficiency, materials selection and indoor environmental quality. Core and Shell encompasses base building elements such as structure, envelope and the HVAC system.
Alexandria continues to innovate and lead the way in green initiatives for its sector, as evidenced by these latest achievements. Silver LEED(R) certification for Core and Shell was also granted for the Company's build-to-suit property located at 681 Gateway, South San Francisco, California as previously announced. This was the first Core and Shell project to be LEED(R) Silver certified in the State of California. Alexandria's state-of-the-art, sustainable building design assures functional and energy efficiency, systems integration, reliability and cost effectiveness.
Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry(R), is the largest owner and pre-eminent first-in-class real estate investment trust focused principally on science-driven cluster formation. Alexandria is the leading provider of high-quality environmentally sustainable real estate, technical infrastructure and services to the broad and diverse life science industry. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biopharmaceutical, medical device, product, service, and translational entities, as well as government agencies. Alexandria's operating platform is based on the principle of "clustering", with assets and operations located in key life science markets.
Last edited:
taal
Senior Member
Sure, but I don't see how it's different then any of the other rumors that are posted without any contention from you. Moreover, it was originated a fairly reputable source working in Mississauga's city council.
If your going to pick and choose what rumors are valid and not please let me know what criteria you're going by ...
taal
Senior Member
Thanks for the insight! Nope, this is all news to me. Particularly, the mech engineering tidbit. It actually explains a lot. You'd really wonder why the project went ahead if they were worried about financing. But that fact above coupled with the major tenant leaving explains it.
Thanks!
Uncle Teddy
Senior Member
At least they can start pretty quickly once the money returns.
argos
Active Member
Update!!
They took down the orange cranes today!! what's going on??
They took down the orange cranes today!! what's going on??
Last edited: